Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead to Present at Upcoming Conferences

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present data on ARC-520, its hepatitis B drug candidate, at two upcoming scientific conferences.

Arrowhead to Present at Upcoming Conferences

Pasadena, CA | Posted on October 18th, 2013

Scheduled conference presentations include the following:

2013 International Meeting on Molecular Biology of Hepatitis B Viruses - Shangai, China, October 20-23, 2013

October 23, 2013 - A poster presentation titled, "Kinetics of knockdown from RNAi therapeutic ARC-520 on hepatitis B virus RNA, DNA, S antigen and e antigen in mice and chimpanzee," will be presented by Christine Wooddell, Ph.D., Senior Scientist;

AASLD - The Liver Meeting - Washington, DC, USA, November 1-5, 2013

November 3, 2013 - A poster presentation titled, "ARC-520 RNAi therapeutic reduces HBV DNA, S and e antigen in a chimpanzee," will be presented by Robert E. Lanford, Ph.D., Texas Biomedical Research Institute.

About ARC-520

Approximately 350 million people worldwide are chronically infected with the hepatitis B virus. Chronic HBV infection can lead to cirrhosis of the liver and is responsible for 80% of primary liver cancers globally. Arrowhead's RNAi-based candidate ARC-520 is designed to treat chronic HBV infection by reducing the expression and release of new viral particles and key viral proteins. The goal is to achieve a functional cure, which is an immune clearant state characterized by hepatitis B s-antigen negative serum with or without sero-conversion. The siRNAs in ARC-520 intervene at the point of DNA transcription, upstream of where nucleotide and nucleoside analogues act. In transient and transgenic mouse models of HBV infection, a single co-injection of Arrowhead's DPC delivery vehicle with cholesterol-conjugated siRNA targeting HBV sequences resulted in multi-log knockdown of HBV RNA, proteins and viral DNA with long duration of effect. In a chimpanzee chronically infected with HBV and high viremia and antigenemia, ARC-520 induced rapid reductions of 90-95% in HBV DNA, e-antigen, and s-antigen. Arrowhead is conducting a phase 1 single ascending dose study in normal volunteers, which the company expects to follow with a phase 2a study in chronic HBV patients.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead's pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

For more information, please click here

Contacts:
Arrowhead Research
Vince Anzalone, CFA
626-304-3400

The Trout Group, LLC
Lauren Glaser
646-378-2972

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Research brief: UMN researchers use green gold to rapidly detect and identify harmful bacteria August 15th, 2018

Particles pull last drops of oil from well water: Rice University engineers find nanoscale solution to 'produced water' problem August 15th, 2018

CTI Materials drives nano commercialization with it's patented surfactant free nanoparticle dispersions August 15th, 2018

Flipping the switch on supramolecular electronics August 14th, 2018

Nanomedicine

Research brief: UMN researchers use green gold to rapidly detect and identify harmful bacteria August 15th, 2018

New technology can detect hundreds of proteins in a single sample: Improvement of barcoding technique offers cost-effective alternative to current technology August 13th, 2018

Scientists squeeze nanocrystals in a liquid droplet into a solid-like state and back again: Simple chemical technique transforms crystal mixture where 2 liquids meet August 9th, 2018

Nanoscience and the future of healthcare kick off first day of ACS national meeting in Boston: Presidential events highlight safety, diversity and groundbreaking research August 2nd, 2018

Announcements

Research brief: UMN researchers use green gold to rapidly detect and identify harmful bacteria August 15th, 2018

Particles pull last drops of oil from well water: Rice University engineers find nanoscale solution to 'produced water' problem August 15th, 2018

How hot is Schrödinger's coffee? August 15th, 2018

CTI Materials drives nano commercialization with it's patented surfactant free nanoparticle dispersions August 15th, 2018

Events/Classes

Kavli Lectures: New vision of nanomaterial synthesis and light-fueled space travel August 8th, 2018

Nanoscience and the future of healthcare kick off first day of ACS national meeting in Boston: Presidential events highlight safety, diversity and groundbreaking research August 2nd, 2018

Leti & CMP Announce World’s First Multi-Project-Wafer Service with Integrated Silicon OxRAM: Oxide-Based Resistive Ram Memory Platform Development for Backend Memories To Offer Non-Volatility Associated with Embedded Designs August 2nd, 2018

Strategic Materials Conference 2018 Highlights “Materials Shaping the Future of Electronics” July 30th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project